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Multiple sclerosis (MS) is a chronic, inflamma-
tory, and demyelinating disease of the central 
nervous system (CNS) characterized by the 
pathological infiltration of autoreactive leuko-
cytes (Frohman et al., 2006; Man et al., 2007; 
McFarland and Martin, 2007). Studies examin-
ing the migratory routes of encephalitogenic 
T cells recently established that they invade 
the submeningeal CNS via perivascular scan-
ning along transvascular pathways that origi-
nate within the meninges (Bartholomäus et al., 
2009). These cells remain perivascularly local-
ized until arriving at Virchow-Robin spaces, 
where access to the CNS parenchyma is accom-
plished via migration across astrocytic endfeet 
that comprise the glial limitans (Abbott et al., 
2006). Restriction of leukocyte entry is thus 
normally accomplished via the presence of lo-
calizing cues along perivascular spaces (Körner 
et al., 1997; Vajkoczy et al., 2001; McCandless 
et al., 2006, 2008b); however, in MS this regula-
tion is lost and cells gain inappropriate access to 
the CNS parenchyma. Recent data examin-
ing the blood–brain barrier (BBB) expression 
of CXCL12, a chemokine that restricts the 
CNS entry of CXCR4-expressing leukocytes 
(McCandless et al., 2006, 2008b), indicate that 
its loss from abluminal surfaces within the CNS 
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Loss of CXCL12, a leukocyte localizing cue, from abluminal surfaces of the blood–brain 
barrier occurs in multiple sclerosis (MS) lesions. However, the mechanisms and conse-
quences of reduced abluminal CXCL12 abundance remain unclear. Here, we show that 
activation of CXCR7, which scavenges CXCL12, is essential for leukocyte entry via endothe-
lial barriers into the central nervous system (CNS) parenchyma during experimental auto-
immune encephalomyelitis (EAE), a model for MS. CXCR7 expression on endothelial barriers 
increased during EAE at sites of inflammatory infiltration. Treatment with a CXCR7 an-
tagonist ameliorated EAE, reduced leukocyte infiltration into the CNS parenchyma and 
parenchymal VCAM-1 expression, and increased abluminal levels of CXCL12. Interleukin 17 
and interleukin 1 increased, whereas interferon- decreased, CXCR7 expression on and 
CXCL12 internalization in primary brain endothelial cells in vitro. These findings identify 
molecular requirements for the transvascular entry of leukocytes into the CNS and suggest 
that CXCR7 blockade may have therapeutic utility for the treatment of MS.
© 2011 Cruz-Orengo et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). 
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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compartments determined that IL-17 and IFN- exhibit an-
tagonistic effects on this process via regulation of CXCR7 
expression at the mRNA level. CXCR7 appears to play an 
essential role in controlling abluminal expression of CXCL12, 
which is necessary to prevent pathological entry of immune 
cells into the CNS parenchyma, and is therefore an attractive 
pharmacologic target for therapeutic treatment of MS.
RESULTS
CXCR7 is expressed exclusively by the CNS vasculature  
during CNS autoimmunity
In prior studies, we observed that CXCL12 internalization 
within CNS postcapillary venules occurred specifically in spec-
imens derived from individuals with CNS autoimmune disease 
(McCandless et al., 2006, 2008a). Given the recent discovery 
that CXCR7 mediates CXCL12 internalization within mam-
malian cells (Naumann et al., 2010), we analyzed spinal cord 
tissues of mice in which one copy of the CXCR7 gene was 
replaced with cDNA encoding enhanced GFP (EGFP; 
CXCR7GFP/+). In the mutated locus, the EGFP gene replaces 
the entire open reading frame encoding exon 2 in CXCR7 
(Fig. S1). GFP expression in naive CXCR7GFP/+ mice was ob-
served throughout the meninges and microvasculature (Fig. 1, 
a and b) and was increased at postcapillary venules during EAE 
induced by adoptive transfer of myelin oligodendrocyte glyco-
protein (MOG)–specific T cells (Fig. 1, c–e). GFP colocalized 
with CD31 in specimens from both naive mice and from those 
with EAE (Fig. 1, f and g). Inflammatory infiltrates were com-
pletely devoid of GFP expression (Fig. 1, c-e, h) even after am-
plification with anti-GFP antibodies (Fig. 1, g and h). Analyses 
of mean numbers of GFP+ venules (Fig. 1 i) and levels of GFP 
expression (Fig. 1 j) within white matter regions of CXCR7GFP/+ 
mice revealed increases in spinal cord (P = 0.04) tissues, but not 
cerebellar and brainstem tissues, of mice with adoptive transfer 
EAE compared with naive animals. Baseline numbers of GFP+ 
venules in the brainstem, however, were significantly higher 
than in the spinal cord (P = 0.0062), reflecting the long known 
increased vascularity of gray matter areas within the CNS 
(Craigie, 1920). Flow cytometric analysis of GFP levels within 
leukocytes derived from secondary lymphoid tissues of MOG-
immunized wild-type and CXCR7GFP/+ detected GFP within 
a small population of CD19+ cells, but not in CD4+, CD8+, 
CD11b+, or CD11c+ cells (Fig. 1 k). Approximately 11 and 4% 
of CD19+ cells exhibited GFP expression in splenic and lymph 
node tissues, respectively, of MOG-immunized mice (Fig. 1 l). 
No GFP expression was observed in any leukocytes in un-
immunized mice (not depicted). Collectively, these data suggest 
that CXCR7 is expressed at endothelial cell barriers within the 
CNS and that this expression is increased in EAE at sites of 
inflammatory infiltration.
CXCR7 antagonism ameliorates EAE and decreases 
leukocyte entry into the CNS parenchyma
Given the predominance of CXCR7 expression on the CNS 
vasculature and its increase in the setting of CNS autoimmune 
is specific to MS (McCandless et al., 2008a,b). Polarized 
CXCL12 expression at the BBB therefore appears to be an 
important component of CNS immune privilege, whereas 
loss of CXCL12 polarity is associated with leukocyte entry. 
The mechanisms responsible for altered CXCL12 expression 
at the CNS microvasculature are unknown; however, studies 
using the murine model of MS, experimental autoimmune 
encephalomyelitis (EAE), implicate several T cell cytokines 
including IL-1, TNF, IFN-, and IL-17 in leukocyte entry 
across the CNS endothelium (Argaw et al., 2006; Afonso 
et al., 2007; Kebir et al., 2007; Lees et al., 2008; McCandless 
et al., 2009; Huppert et al., 2010), suggesting they may influ-
ence localizing cues at this site.
Recently, CXCR7 (formerly RDC-1) has been identi-
fied as an alternative receptor for CXCL12 that also binds 
CXCL11 (Burns et al., 2006). CXCR7 possesses homology 
with conversed domains of G protein–coupled receptors 
(GPCRs; Libert et al., 1990) and is structurally similar to other 
CXC receptors, although ligand binding does not initiate 
typical intracellular signal transduction, but instead results 
in -arrestin recruitment and MAP kinase activation (Zabel 
et al., 2009; Rajagopal et al., 2010). CXCR7 expression stud-
ies have identified protein on the surface of B cells (Infantino 
et al., 2006; Sierro et al., 2007) and transcripts within the 
heart, kidney, and spleen (Burns et al., 2006) and in the adult 
CNS, within hippocampal neurons and extensively along the 
microvasculature (Schönemeier et al., 2008a). Studies in 
zebrafish development and in in vitro mammalian systems 
suggest CXCR7 functions primarily to sequester CXCL12 
(Boldajipour et al., 2008; Mahabaleshwar et al., 2008; 
Naumann et al., 2010), thereby regulating signaling through 
CXCR4. No studies, however, have explored in vivo roles for 
CXCL12 sequestration within mammals in either physiologi-
cal or diseased states. The coexpression of this chemokine/ 
receptor pair at the CNS microvasculature suggests a potential 
mechanism for regulating CXCL12 localization along ablu-
minal surfaces, and therefore immune privilege at the BBB.
In this study, we provide the first report of the role of 
CXCR7 in an in vivo disease model and provide insight into 
the mechanism of CXCL12 internalization at the BBB. 
We examined the expression and activity of CXCR7 in CNS 
tissues, using both in vivo and in vitro model systems. The 
results described here demonstrate that CXCR7 is critical in 
mediating CXCL12 internalization at CNS endothelial bar-
riers in the autoimmune model EAE. In vivo antagonism of 
CXCR7 inhibited induction of EAE in a dose-dependent 
manner, while ameliorating ongoing disease. Compared with 
vehicle-treated animals, mice treated with CXCR7 antago-
nist were found to have decreased parenchymal and perivas-
cular infiltrates, with accumulation of immune cells within 
the subarachnoid space, adjacent to meningeal vessels. Vehicle-
treated mice with EAE showed attenuated abluminal CXCL12 
expression, whereas EAE mice treated with high doses of 
antagonist retained perivascular CXCL12 expression pat-
tern. Studies evaluating the impact of T cell cytokines on 
CXCR7-mediated sequestration of CXCL12 into lysosomal 
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animals treated with vehicle alone beginning at the time of 
adoptive transfer. Disease expression in adoptively transferred 
animals treated with vehicle was no different from similarly 
transferred animals that remained untreated (not depicted). 
The mean maximal disease severity scores of all groups of 
CCX771-treated versus vehicle-treated were also significantly 
lower (P < 0.001) and differences in disease and weight loss 
curves between groups of animals treated with 10 and 
30 mg/kg doses of CCX771 were also significant (P < 0.001; 
Fig. 2, b and c).
Given that the CXCR7 antagonist CCX771 reduced 
clinical disease severity when administered at the time of 
adoptive transfer of MOG-specific T cells, we wondered 
whether CXCR7 antagonism could treat ongoing EAE. 
Thus, we compared treatment with vehicle alone with treat-
ment with vehicle until day 9 after transfer, when animals 
have attained a score of 1, and then began treatment with 
10 mg/kg of CCX771. We found that CCX771 significantly 
reduced the clinical severity of peak disease and improved the 
recovery of diseased animals compared with vehicle-treated 
disease, we hypothesized that CXCR7 would impact on the 
localization of infiltrating immune cells via loss of CXCL12 
as a localizing cue within perivascular locations. Accordingly, 
disruption of this process might allow abluminal CXCL12 to 
persist, preventing perivascular leukocytes from gaining access 
to the CNS parenchyma. To test this, we administered various 
doses of a small molecule inhibitor of CXCR7, CCX771, 
daily to mice beginning at the time of adoptive transfer of 107 
MOG-specific CD4+ T cells and continued throughout the 
course of clinical disease. CCX771 exhibits high affinity for 
human and mouse CXCR7 (11 nM; Zabel et al., 2009) and 
is completely selective relative to all other chemokine, chemo-
tactic, and nonchemokine GPCRs tested (>10 µM; Tables  
S1 and S2). Subcutaneous, daily administration of CCX771 at 
the doses used in our studies results in high systemic exposure 
with a serum half-life of 6 h (Fig. S2 a) and efficient penetra-
tion into the CNS, as determined by LC-MS (Carbajal et al., 
2010). Administration of CCX771 at doses of 5, 10, and 
30 mg/kg led to a dose-dependent decrease in clinical disease 
severity (Fig. 2 a) and weight loss (Fig. 2 b) compared with 
Figure 1. CXCR7 is expressed by endothelial cells within the CNS and B cells within lymphoid tissues. Spinal cord sections derived from naive 
CXCR7GFP/+ mice (a, b, and f) and from those with EAE (c–e, g, and h) were evaluated via confocal microscopy for GFP fluorescence alone (green; a–d) or 
with expression of CD45 (red; e) and, after amplification with anti-GFP antibodies, in conjunction with detection of CD31 (f and g) and CD45 (h). All nuclei 
are counterstained with ToPro3 (blue). Bars, 25 µm. Quantitation of mean numbers of GFP+ venules (i) and mean GFP levels (j) in spinal cord (SC), brain-
stem (BS), and cerebella (CB) of naive or EAE CXCR7GFP/+ mice are shown. Data are expressed as the mean intensity per vessel for n = 12 images taken 
from 3 mice/group. *, P < 0.01. Flow cytometric analysis of expression of GFP and leukocyte markers in cells derived from spleens (top) and lymph nodes 
(LNs, bottom) of MOG-immunized wild-type (red lines) and CXCR7GFP/+ (black lines) mice (k). (l) Spleen and LN cells were stained with indicated antibodies; 
numbers indicate percentages of CD19+ cells expression GFP. Data are representative of two experiments with three mice per group.
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CCX771, which did not exhibit any meningeal inflammation 
(Fig. 3 b). In addition, detection of VCAM-1 and GFAP in 
mice treated with vehicle versus CCX771, regardless of dose, 
revealed meningeal VCAM-1 expression in all animals, but no 
parenchymal VCAM-1 expression in mice that received an-
tagonist, despite similar levels of GFAP+ expression in all mice 
(Fig. 3 b). Analysis of the overall width of meningeal infiltrates 
in 10 consecutive images under high power magnification re-
vealed significant increases in mice treated with 10 or 5 mg/kg 
CCX771 versus mice treated with vehicle or left untreated 
(P = 0.0003 and 0.0243, respectively; Fig. 3 c). Quantitative 
assessment of the numbers of perivascular cuffs (designated as 
“lesions”) per 10 consecutive high power fields in each sec-
tion revealed significantly fewer lesions in mice treated with 
CCX771 at 10 mg/kg versus nontreated or vehicle-treated 
mice (P = 0.0114; Fig. 3 d). Analysis of numbers of leukocytes 
within perivascular cuffs observed in spinal sections from all 
treatment groups showed that CXCR7 antagonism led to 
significantly fewer lesions with extensive cuffing (P = 0.0021, 
score 2; P = 0.0142, score 3; Fig. 3 e).
IHC identification of subsets of infiltrating leukocytes 
revealed many CD3+ and CD11b+ cells within the meninges 
of mice with EAE treated with vehicle or with 10 mg/kg of 
CCX771, whereas mice treated with 30 mg/kg of CCX771 
exhibited almost no CD3+ and CD11b+ cells at this location 
(Fig. 4 a). Few B220+ cells were observed within the menin-
ges of either vehicle or CCX771-treated animals (Fig. 4 a). 
Although vehicle-treated mice exhibited infiltration of CD3+ 
and CD11b+ cells within the parenchyma, mice treated with 
10 mg/kg CXCR7 antagonist exhibited predominantly 
CD11b+ cell parenchymal infiltration, whereas both CD3+ 
and B220+ cells accumulated within the meninges (Fig. 4 a). 
Analysis of leukocyte subsets within deep white matter 
animals, even if CCX771 treatment began when all animals 
had reached a score of 1 (P = 0.0146; Fig. 2 d). Analysis of 
weight loss in both groups also revealed a significant differ-
ence between vehicle and the antagonist treated groups (P < 
0.001; Fig. 2 e), as did analysis of mean maximal disease sever-
ity scores (Fig. 2 f). These data strongly implicate CXCR7 as 
a disease-modifying molecule.
CXCR7 antagonism prevents leukocyte entry  
at the microvasculature
To examine the basis of our clinical findings, we analyzed spi-
nal cord tissues from animals with EAE that had undergone 
no treatment, treatment with vehicle or with various doses of 
CCX771. Histological examination of spinal cord sections 
from vehicle- and CCX771-treated (10 mg/kg) mice with 
EAE at the peak of their relative disease curves (12 d after 
transfer), revealed dramatic differences in the extent of men-
ingeal and parenchymal inflammatory white matter lesions, 
whereas animals treated with high dose CCX771 (30 mg/kg) 
exhibited no meningeal or parenchymal infiltrates (Fig. 3 a). 
Similarly, luxol fast blue (LFB) analysis of spinal cord tissues 
revealed decreased demyelination in mice treated with 10 or 
30 mg/kg of CCX771 compared with vehicle-treated ani-
mals (Fig. S2 b). To assess the differences in meningeal inflam-
mation between treatment groups, we used the astrocyte 
activation marker glial fibrillary acidic protein (GFAP) to de-
lineate the edge of the parenchyma.
Immunohistochemical (IHC) detection of VCAM-1 and 
GFAP in mice treated with vehicle versus CCX771 during 
adoptive transfer of MOG-specific T cells revealed that mice 
treated with 10 mg/kg CCX771 exhibited marked increases 
in numbers of cell localized to the meninges compared with 
vehicle-treated mice and to mice treated with 30 mg/kg 
Figure 2. CXCR7 antagonism decreases 
the clinical severity of EAE. Mice were in-
travenously injected with 10 × 106 MOG-
specific CD4+ T cells, and dose response 
effects of CCX771 on disease induction (a–c) 
and treatment of ongoing disease (d–f) were 
examined. For dose-response curves evaluat-
ing clinical disease severity and weight loss  
(a and b), animals were grouped into those 
receiving vehicle or CCX771 at indicated doses 
daily, beginning at the time of adoptive trans-
fer of MOG-specific CD4+ T cells. Mice were 
monitored daily, weighed, and graded on a 
scale of 0–5, as described previously  
(McCandless et al., 2009). Numbers in paren-
theses indicated number of mice with disease 
compared with total mice in each group. Re-
sults are expressed as mean disease scores ± 
SEM, and curves were analyzed using one-
way ANOVA compared with vehicle–treated mice. **, P < 0.001. (c) Mean maximal disease severity scores for animals treated with vehicle or CCX771 at 
indicated doses. *, P < 0.05; **, P < 0.01; ***, P < 0.001. To determine whether CCX771 ameliorates ongoing EAE and weight loss (d and e), animals were 
grouped into those receiving vehicle or vehicle until animals reached a score of 1 and then CCX771 at 10 mg/kg. Results are expressed as mean disease 
scores ± SEM and analyzed via one-way ANOVA. **, P < 0.001. (f) Mean maximal disease severity scores for animals treated with vehicle or with vehicle 
until development of disease and then CCX771 at 10 mg/kg. **, P < 0.01. Data are representative of five experiments with n = 10–13 animals per group.
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lines exhibited identical levels of proliferation and cytokine 
expression during antigen-specific reactivation in vitro (Fig. S3). 
Analysis of cytokine expression within the spinal cord tissues 
of vehicle versus CCX771-treated mice at the peak of disease 
revealed no differences in levels of T cell cytokines (Fig. S4 a), 
suggesting that T cells within both meningeal and parenchy-
mal compartments express similar levels of proinflammatory 
cytokines. Collectively, these data indicate that CXCR7 an-
tagonism ameliorates EAE by preventing the parenchymal 
entry of leukocytes specifically via effects at the CNS micro-
vasculature and that this limits the overall trafficking and 
entry of leukocytes to the CNS.
T cell cytokines regulate internalization of CXCL12 by brain 
endothelial cells via CXCR7
Previous studies showed that T cell–derived IL-1 contrib-
utes to leukocyte CNS entry and disease severity during 
EAE via loss of abluminal CXCL12 at the BBB (McCandless 
et al., 2009). CXCL12 removal from cell surfaces may occur in 
mammalian systems via CXCR7-mediated trafficking to lyso-
somes for degradation (Luker et al., 2010). Thus, we won-
dered whether various T cell cytokines might contribute to 
leukocyte egress through alterations in the expression or se-
questration of CXCL12, with the latter occurring via regula-
tion of the expression and/or activity of CXCR7. To test this 
perivascular cuffs of vehicle versus CCX771-treated mice 
with EAE revealed a dose-dependent decrease in the numbers 
of infiltrating CD3+ (P = 0.0158, 10 mg/kg; P = 0.0068, 
30 mg/kg), CD11b+ (P = 0.0124, 10 mg/kg; P = 0.0033, 
30 mg/kg), and B220+ (P < 0.0001, 30 mg/kg) cells (Fig. 4, 
b and c). Consistent with this, the majority of TNF expression 
was detected primarily within the meninges in CCX771-
treated mice, whereas vehicle-treated mice also exhibited 
TNF expression in the parenchyma (Fig. 4 d). Collectively, 
these data suggest that CXCR7 antagonism is associated with 
loss of parenchymal VCAM-1 expression, preventing in-
flammatory infiltration at the level of the microvasculature 
and leading to accumulation of mononuclear cells within 
the meninges.
To determine whether CXCR7 antagonism affected the 
percentages and overall numbers of mononuclear subsets 
within the spinal cord parenchyma, we performed flow cyto-
metric analyses of cells isolated from spinal cord tissues of vehicle 
and CCX771-treated (10 mg/kg) mice at the peak of disease. 
CXCR7 antagonism led to a decrease in both the percentages 
and total cell numbers of infiltrating CD4+, CD11b+, and B220+ 
cells (Fig. 4, e and f). Analysis of CD45+CD11b+ popula-
tions revealed significant decreases in both activated microglia 
(CD45hiCD11blow) and macrophages (CD45hiCD11bhi; Fig. 4 f). 
Vehicle-exposed versus CCX771-exposed MOG-specific T cell 
Figure 3. CXCR7 antagonism prevents 
leukocyte entry at the microvasculature. 
(a) Histological analyses of spinal cord tissues 
from vehicle- and CCX771-treated (10 or 30 
mg/kg) mice 12 d after MOG-specific CD4+  
T cell transfer. Note perivascular cuffs in vehicle 
treated tissue section (arrows). Bars, 25 µm. 
(b) IHC and confocal imaging detection of 
GFAP (red) and VCAM-1 (green) within menin-
ges (top images) and white matter (bottom 
images) of animals with EAE treated with vehicle 
(left) versus CCX771 at 10 or 30 mg/kg. Nuclei 
were counterstained with ToPro3 (blue).  
(inset) Isotype control (IC). Higher magnification 
images of boxed areas on lower power images 
of meninges from mice treated with vehicle 
and 10 mg/kg CCX771 are provided to the right 
of merged images. Note the lack of astrocyte 
but not meningeal (arrowheads) expression of 
VCAM-1 in CCX771-treated tissues. Analyses 
were performed on spinal cords harvested 
from three animals per group at peak of dis-
ease. Bars, 25 µm. Quantitation of meningeal 
width (c), lesion number (d), and lesion char-
acteristics (e) in mice from four treatment 
groups: none (white bars), vehicle (light gray 
bars), CCX771 at 5 mg/kg (dark gray bars), and 
10 mg/kg (black bars). Scoring of perivascular 
cuffs: 1 = 2–6 cells; 2 = 6–11 cells; 3 > 11 cells. 
n = 5 mice/group; data expressed as mean 
width (millimeters; c), number of white matter 
(WM) lesions (d), or number of lesions of each 
score (e) ± SEM. *, P < 0.05.
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treated with various doses of IL-17, IL-1, IFN-, and TNF 
were evaluated for expression of CXCL12, CXCR4, and 
CXCR7 and the lysosomal-associated membrane protein 
directly, we evaluated brain endothelial cell responses to T cell 
cytokines relevant to altered BBB during CNS autoimmu-
nity. Primary brain microvessel endothelial cells (BMECs) 
Figure 4. CXCR7 antagonism limits leukocyte trafficking to the CNS. IHC analyses of infiltrating leukocytes expressing CD3, CD11b, or B220 in 
respect to activated astrocytes (red, GFAP) within the meninges (a) and white matter (b) of vehicle-treated versus CCX771-treated (10 or 30 mg/kg) mice 
with EAE. Nuclei were counterstained with ToPro3 (blue). Bar, 10 µm. Analyses were performed on spinal cords harvested from three animals per group at 
peak of disease. (c) Quantitative analysis of numbers of white matter lesions attributed to the infiltration of CD3+, CD11b+, and B220+ cells within spinal 
cord tissues of vehicle-treated and CCX771-treated (10 or 30 mg/kg) mice with EAE. Data are presented as the mean numbers of lesions in n = 3 mice per 
group ± SEM. (d) IHC analysis of infiltrating leukocytes (red, CD45) in respect to TNF expression (green) in spinal cords of vehicle-treated versus CCX771-
treated (10 mg/kg) mice with EAE. Nuclei were counterstained with ToPro3 (blue). Bar, 25 µm. (e and f) Flow cytometric analysis of percentages (e, num-
bers in quadrants) and total cell numbers (f) of CD4+, CD8+, CD45+, CD11b+, CD11c+, and B220+ leukocytes harvested from spinal cords of vehicle-treated 
versus CCX771-treated (10 mg/kg) mice. Data depicting total cell numbers are presented as the mean numbers of cells derived from spinal cords of  
vehicle-treated versus CCX771-treated mice with EAE ± SEM from three experiments with five mice per group. *, P < 0.05; **, P < 0.01.
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Figure 5. CXCR7 expression and CXCL12 internalization are altered by T cell cytokines. (a) Primary BMECs were treated with indicated doses of IL-17, IL-1, 
IFN-, and TNF, and expression of CXCL12, CXCR4, CXCR7, LAMP-1, and LAMP-2 mRNA were measured via QPCR. Data from three experiments with triplicates are 
presented as the mean fold change in mRNA levels over untreated controls ± SEM. *, P < 0.05; **, P < 0.001. (b) BMECs derived from CXCR7GFP/+ mice were treated with 
cytokines (IL-1, IL-17, IFN-, and TNF) or VEGF (100 ng/ml) or left untreated (control), and CD31 (red) and GFP (green) expression was evaluated. Nuclei counter-
stained with ToPro3 (blue). Bar, 10 µm. (c) Quantitative analysis of GFP expression in cytokine- or VEGF-treated CD31+ CXCR7GFP/+BMECs. Data from three experiments 
performed in triplicate and presented as the mean fold change in GFP expression over untreated BMECs ± SEM. *, P < 0.05; **, P < 0.001. (d) LAMP-1 (green) and 
CXCL12 (red) colocalization in BMECs left untreated (control) or treated with IFN-, IL-1, and IL-17. Bar, 10 µm. (e) Quantitation of CXCL12 and colocalization of 
CXCL12 and LAMP-1 staining in control and IL-1–, IL-17–, and IFN-–treated BMECs. Data from three experiments in which five images were analyzed in each of 
three replicates per treatment group and presented as mean fold change over untreated controls. *, P < 0.05; **, P < 0.001.
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(LAMP)-1 and LAMP-2, which are components and mark-
ers of the lysosomal membrane, via quantitative RT-PCR 
(QPCR; Fig. 5 a). IL-17 led to a significant increase in 
CXCR7 mRNA levels (P = 0.025), whereas both IL-1 and 
IFN- led to dose-dependent decreases in the mRNA levels 
of both CXCR4 and CXCR7 (P < 0.01 for all comparisons; 
Fig. 5 a, top and bottom). Similarly, BMECs derived from 
CXCR7GFP/+ mice treated with high doses of cytokine and 
assessed for changes in GFP expression via quantitative con-
focal microscopic analysis exhibited significantly increased 
GFP expression after treatment with IL-17 (P = 0.013) and 
decreased GFP expression after treatment with IFN- (P = 
0.0003; Fig. 5, b and c). In contrast with the QPCR results, 
levels of GFP expression were not affected by IL-1, but were 
decreased by treatment with TNF (P = 0.015; Fig. 5, a–c). 
BMEC CXCL12 expression was significantly increased by 
treatment with either IL-1 (P = 0.0006) or TNF (P = 0.005; 
Fig. 5 a, right top and bottom), but was decreased by treat-
ment with IFN- (P = 0.019; Fig. 5 a, bottom left). LAMP-1 
and LAMP-2 mRNA levels were not significantly altered by 
cytokines (Fig. 5 a). Colocalization of CXCL12 and LAMP-1 
within BMECs, as assessed by confocal IHC analysis, was sig-
nificantly increased by treatment with IL-17 (P = 0.014) or 
IL-1 (P = 0.0007; Fig. 5, d and e), whereas treatment with 
IFN- decreased CXCL12 internalization.
To specifically analyze the sequestration of extracellular 
CXCL12, we evaluated cytokine-mediated uptake of exoge-
nous fluorescent CXCL12-mCherry fusion protein via con-
focal IHC. This fusion protein exhibits CXCR4-binding 
kinetics and signaling comparable to unfused CXCL12 and 
has been used to quantify inhibition of CXCR7 binding by 
antagonists (Luker et al., 2009; Naumann et al., 2010). Expo-
sure of BMECs to 300 ng/ml CXCL12-mCherry, but not 
mCherry alone, leads to colocalization of the fusion protein 
with LAMP-1 (Fig. 6 a). Analysis of BMECs treated with 
IL-1 (P < 0.0001) and IL-17 (P < 0.0001) revealed signifi-
cant increases in CXCL12-mCherry internalization over 
those left untreated or treated with IFN- (Fig. 6, a and b). 
Internalization of CXCL12-mCherry in IL-1–treated (P = 
0.002) or IL-17–treated (P = 0.016) BMECs exhibited dose-
dependent inhibition by CCX771 (Fig. 6 c), indicating that 
this process is mediated by CXCR7. Consistent with this, 
examination of CXCL12-mCherry internalization within 
lysosomes in BMECs exposed to a neutralizing, anti-CXCR4 
antibody did not demonstrate a role for CXCR4 in this pro-
cess (Fig. S4 b). Taken altogether, these data indicate that T cell 
cytokines regulate the levels of extracellular CXCL12 via ef-
fects on the expression of chemokine or on expression or activ-
ity of CXCR7.
Endothelial cell internalization of CXCL12 leads to its 
colocalization with CD31 in spinal cord postcapillary venules in 
mice with EAE induced by active immunization (McCandless 
et al., 2006), whereas mice with adoptive transfer EAE exhibit 
complete loss of CXCL12 at this site (Fig. S5 a). Use of 
CXCR7GFP/+ mice to evaluate CXCL12 expression patterns 
revealed similar results as those observed using CD31 to 
identify vessels with abluminal CXCL12 observed in naive 
animals and lack of CXCL12 at sites of lesions in mice with 
adoptive transfer EAE (Fig. S5 b). Thus, to determine whether 
CXCR7 antagonism altered the BBB expression of CXCL12 
in vivo, we analyzed the kinetics of CXCL12 removal at the 
CNS vasculature at various time-points posttransfer of encepha-
litogenic T cells. Similar amounts of abluminal CXCL12 around 
CD31+ postcapillary venules was observed in the spinal cords 
of mice from both treatment groups at day 2 after transfer of 
MOG-specific T cells, but was completely absent by day 8 in 
mice treated with vehicle. Animals treated with CXCR7 antag-
onist (10 mg/kg) exhibited persistent abluminal CXCL12 
until 10 d after transfer (Fig. 6, d and e). Analysis of panCXCL12 
mRNA levels in IL-1–treated BMECs exposed to vehicle 
versus CCX771 and CXCL12 (Stumm et al., 2002) mRNA 
levels in spinal cords derived from mice at peak clinical dis-
ease (day 10) revealed no effects of antagonist on CXCL12 
expression (Fig. S6), suggesting that the increased CXCL12 
protein observed during CXCR7 antagonism is caused by 
blockade of its internalization by CNS endothelium.
DISCUSSION
The current study provides compelling evidence that 
CXCR7-mediated internalization of CXCL12 is critical for 
the parenchymal infiltration of autoreactive leukocytes during 
CNS autoimmunity and that IL-17, IFN-, and IL-1 regu-
late this process via alterations in CNS endothelial cell ex-
pression of CXCL12 and CXCR7. This is supported by both 
in vitro and in vivo experiments in which CXCR7 antago-
nism prevented the endothelial cell internalization and lyso-
somal delivery of CXCL12, leading to increased extracellular 
levels of the chemokine. In vitro, endothelial cell internaliza-
tion of CXCL12 was augmented by treatment with IL-17 
and IL-1, decreased by IFN-, and completely blocked by 
CXCR7 antagonism. In vivo, endothelial cell CXCR7, which 
was detected exclusively at post-capillary venules within 
murine CNS tissues, exhibited increased expression at this 
location in specimens derived from mice with EAE induced 
by the adoptive transfer of MOG-specific T cells. Most strik-
ingly, administration of a CXCR7 antagonist during induc-
tion of EAE led to a dose-dependent inhibition of disease 
severity and promotion of recovery and complete ameliora-
tion of symptoms when administered to mice during ongo-
ing disease. The in vivo effect of CXCR7 antagonism during 
EAE was associated with inhibition of leukocyte trafficking 
from leptomeningeal vessels to the microvasculature, leading 
to a significant widening of meningeal infiltrates and a sig-
nificant decrease in the numbers and extents of parenchymal 
infiltrates. This latter effect of CXCR7 antagonism was also 
associated with a complete loss of VCAM-1 up-regulation 
by spinal cord astrocytes, an essential step in the parenchymal 
entry of leukocytes during EAE (Gimenez et al., 2004). These 
are the first in vivo data demonstrating a role for CXCR7-
mediated internalization of CXCL12 in an autoimmune dis-
ease, identifying the receptor as a putative therapeutic target 
for MS.
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CXCR7 cycles continuously between the cell surface and 
endosomal compartments and is rapidly replenished from in-
tracellular stores after ligand-induced internalization (Naumann 
et al., 2010). In the normal adult brain, CXCR7 mRNA is 
expressed by neurons and endothelial cells (Schönemeier 
et al., 2008a). Although factors that regulate CXCR7 mRNA 
expression within the CNS endothelium are unknown, they 
are likely to involve inflammatory pathways, as permanent 
Several studies suggest that CXCR7 primarily functions 
to internalize CXCL12 to efficiently transduce changes in 
chemokine gene expression, and thereby stringently regulate 
CXCR4 signaling. Although this function has been well 
characterized during zebrafish development (Valentin et al., 
2007; Boldajipour et al., 2008), recent in vitro studies suggest 
CXCR7 also sequesters CXCL12 in mammals (Luker et al., 
2010; Naumann et al., 2010). Consistent with this function, 
Figure 6. BMEC internalization of CXCL12 is mediated by CXCR7. (a) BMECs were left untreated (control) or treated overnight with IL-1 (10 ng/ml), 
IL-17 (100 ng/ml), or IFN- (100 ng/ml) and internalization of CXCL12-Cherry (red, L12mCherry; left) versus mCherry alone (inset) via colocalization with 
LAMP-1 (green). Nuclei were counterstained with ToPro3 (blue) Magnification 40×. Bar, 20 µm. (b) Fold changes in internalization of CXCL12-Cherry in 
BMECs treated with IL-1 (10 ng/ml), IL-17 (100 ng/ml), or IFN- (100 ng/ml) over those left untreated. (c) Fold changes in internalization of CXCL12-
Cherry in IL-1– and IL-17–treated BMECs left unexposed or exposed to 10 nM or 100 nM (filled bars) CCX771. All quantitative data are presented as 
mean ± SEM for an experiment done in triplicate, and are representative of three to four experiments. **, P < 0.001; *, P < 0.05. (d) Detection of CD31 
(green) and CXCL12 (red) within spinal cords of mice treated with vehicle or CCX771 (10 mg/kg for all bottom panels except for the far right panel, which 
is from a mouse treated with 30 mg/kg) at 2, 4, 6, 8, and 10 d after transfer of MOG-specific CD4+ T cells. Nuclei have been counterstained with Topro3 
(blue). Bar, 20 µm. IC, isotype control. Data are representative of 10 images each from 3 mice per treatment group per time point. (e) Quantitative analysis 
of CXCL12 expression on CD31+ venules within the spinal cords of mice at various days after transfer of MOG-specific T cells. Data derived from venules 
analyzed within four to eight images per spinal cord for three mice per treatment group for each time point, and are expressed as the mean ratios of 
signal intensity of CXCL12/CD31 ± SEM. **, P < 0.001 and *, P < 0.05 for comparisons between treatment groups on the same day after transfer; #, P < 0.05  
for comparisons between days 2 and 8 after transfer within a treatment group.
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for the development of novel therapies for this disease. How-
ever, the targeting of molecules expressed by immune cells 
may not be specific for the CNS, as natalizumab also targets 
gastrointestinal-homing lymphocytes (Baron et al., 1993). 
In addition, natalizumab treatment is associated with progres-
sive multifocal leukoencephalopathy (PML), an opportunistic, 
fatal encephalitis caused by JC virus (Clifford, 2008). Our data 
indicate that targeting CXCR7 specifically inhibits lympho-
cyte entry into the CNS via effects on the CNS microvascu-
lature in both the meningeal and parenchymal compartments. 
The lack of inflammation at high doses of CCX771 suggests 
that CXCR7 is required for entry of cells into the meningeal 
compartment, which is the first site of leukocyte accumula-
tion during neuroinflammation. Thus, low-dose CCX771 
partially blocked leukocyte recruitment, allowing meningeal 
accumulation, whereas high-dose CCX771 completely abro-
gated leukocyte localization at both sites. In addition, CXCR7 
antagonism prevented lymphocyte egress via persistent BBB 
expression of CXCL12, effectively diminishing parenchymal 
responses to T cell cytokines, such as TNF, which are required 
for astrocyte expression of VCAM-1 (Gimenez et al., 2004). 
Studies examining CXCR7 antagonism in the contexts of 
acute and chronic CNS infections will reveal additional in-
sights regarding the safety of this approach.
In summary, our study provides evidence that CXCR7-
mediated sequestration of CXCL12 at the CNS vasculature 
regulates leukocyte localization at this site during CNS auto-
immunity. We also provide evidence that the differential re-
sponses of CNS regions to varying ratios of Th1 versus Th17 
cells during induction of autoimmunity may be caused by 
opposing effects of IFN- and IL-17 on BBB CXCR7 ex-
pression. Thus, the ubiquitous expression of CXCR7 at CNS 
postcapillary venules may provide a molecular switch that pre-
serves or destroys barriers to leukocyte entry, depending on 
the cytokine milieu. Targeting CXCR7 may therefore pro-
vide additional specificity for the prevention of lymphocyte 
egress regardless of the cytokine profile associated with dis-
ease expression (Axtell et al., 2010).
MATERIALS AND METHODS
Animals and antibodies. C57BL/6 (The Jackson Laboratory) and 
CXCR7GFP/+ mice were maintained in pathogen-free conditions (Depart-
ment of Comparative Medicine, Washington University, St. Louis, MO), and 
studies were performed in compliance with the guidelines of the Washington 
University School of Medicine Animal Safety Committee. Antibodies used 
include CXCL12 rabbit polyclonal (PeproTech), actin antibodies (Sigma- 
Aldrich), IgG isotype (Jackson ImmunoResearch Laboratories), monoclonal 
rat anti–mouse-CD31, CD11b, Thy1.1, VCAM-1 (BD), anti-CD3 (Dako), 
anti-B220 (R&D Systems), GFAP (Zymed), LAMP-1 (US Biologicals), GFP 
(Invitrogen), and fluorescently conjugated antibodies against CD4, CD8, 
CD19, CD11b, CD11c, B220, and CD45 (BD).
Generation of CXCR7 knock-in mice. The entire open reading frame 
of Cxcr7 gene encoded by exon 2 was replaced by EGFP sequence. A 5 ho-
mology arm containing a 5.4-kb genomic fragment containing part of intron 
1 and 26 bp of exon 2 immediately upstream of the ATG start codon was 
PCR amplified using C57BL/6 genomic DNA as templates, and then cloned 
in front of EGFP coding sequence. A 3 homology arm containing a 5.2-kb 
middle cerebral artery occlusion leads to increased CXCR7 
mRNA within vascular elements of the ipsilateral cortex 
(Schönemeier et al., 2008b). Consistent with this, we ob-
served increased levels of expression of CXCR7 along the 
microvasculature during EAE and after in vitro treatment of 
BMECs with IL-17, a T cell cytokine implicated in the traf-
ficking of immune cells into the CNS parenchyma (Kebir 
et al., 2007; Fabis et al., 2008; Huppert et al., 2010). IL-17 and 
IL-1, another cytokine implicated in T cell entry early in the 
course of EAE (Sutton et al., 2006), also promoted the inter-
nalization of CXCL12 and its colocalization with LAMP-1 
within BMECs, supporting the notion that proinflammatory 
cytokines regulate localizing molecules at the BBB. IFN-, 
however, decreased BMEC expression of CXCL12, CXCR4, 
and CXCR7. These results are consistent with prior reports 
that IFN- down-regulates CXCR4 in neutrophils and the 
homeostatic chemokines CXCL13 and CCL21 in lymphoid 
tissues (Nagase et al., 2002; Mueller et al., 2007). Thus, al-
though CXCR7 and CXCL12 likely exist in equilibrium 
under homeostatic conditions, preserving localizing cues that 
slow leukocyte egress into the parenchyma, inflammatory cyto-
kines may differentially shift this equilibrium in favor of pre-
venting or promoting leukocyte entry.
Studies examining the role of T cell cytokines in the loca-
tion of inflammatory lesions during EAE have determined that 
IL-17 is also essential for brainstem inflammation (Kroenke 
et al., 2010). In our study, levels of CXCR7 in all white matter 
regions were similar in naive mice whereas mice with EAE 
exhibited significant increases in CXCR7 expression in spinal 
cord and cerebellum. In contrast, levels of CXCR7 expres-
sion remained unchanged from baseline with the brainstem, 
a CNS region that typically does not develop any inflamma-
tory lesions in classical EAE models. Of interest, transfer 
of MOG-specific T cells that express high levels of IL-17 
induce more brain inflammation and atypical EAE (Stromnes 
et al., 2008). Our data demonstrating that high levels of 
IL-17 induce CXCR7 expression in BMECs suggest that this 
cytokine may differentially affect leukocyte entry in various 
CNS regions through effects on CXCR7-mediated internal-
ization of CXCL12 at the microvasculature. Further studies 
using tissue-specific transgenic approaches are planned to fur-
ther define the in vivo effects of Th17 cells on CXCR7, 
CXCR4, and CXCL12 location and activity at the BBB during 
EAE. Although we did not detect CXCR7 expression by in-
filtrating leukocytes within the CNS, we did identify a sub-
population of CD19+ cells that expressed CXCR7 within 
lymphoid tissues in MOG-immunized animals. Thus, CXCR7 
may play a role in the early adaptive immune responses of B 
cells, as suggested by a previous study (Infantino et al., 2006).
Infiltrating, autoreactive leukocytes require binding of in-
tegrin 41 (VLA-4) to VCAM-1 for entry into CNS paren-
chyma (Yednock et al., 1992; Baron et al., 1993). The success 
of natalizumab, a humanized monoclonal antibody against 
4-integrin, in preventing new lesion formation in MS pa-
tients (Belachew et al., 2011) indicates that targeting mole-
cules involved in leukocyte entry is indeed a tractable approach 
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and anti-IL-4, as previously described (Gimenez et al., 2006). During the 
third restimulation, T cells were treated for 4 d with various doses of CCX771 
(ChemoCentryx) versus vehicle (DMSO) or CCX704, an inactive CXCR7 
antagonist, and then evaluated for proliferation and cytokine expression. For 
proliferation responses, T cells were preloaded with CFSE (Invitrogen) before 
third restimulation. For cytokine responses, supernatants of restimulated cells 
were evaluated for Th1/Th2/Th17 cytokine expression via cytokine bead 
array (BD). Data acquisition for CFSE labeling and cytokine expression panel 
was performed via BD FACSCalibur flow cytometry and analyzed by BD 
FCAP Array software.
QPCR analysis of spinal cord expression. Total RNA was prepared and 
QPCR was performed as previously described (Klein et al., 2005) using 
primers for TNF, IFN-, IL-10, IL-17, and IL-1, whose sequences have 
been previously published (Klein et al., 2004, 2005).
Preparation of murine BMECs. Murine BMECs were generated using 
previously described methods (Perrière et al., 2005), with slight modifica-
tions. In brief, cortices of 8-wk-old C57BL/6J mice were dissected free of 
meninges, minced, and digested with 1 mg/ml collagenase CLS2 (Worthing-
ton) and 30 U/ml DNase (Sigma-Aldrich) at 37°C for 45 min, with shaking. 
The digested cell pellet was separated by centrifugation in 20% BSA in DME 
(1,000 g for 20 min), followed by a further digestion in 1 mg/ml collagenase-
dispase (Roche) and 10 U/ml DNase at 37°C for 30 min, with shaking. 
Microvessel fragments were subsequently isolated on a 33% continuous Per-
coll gradient (1,000 g for 10 min), washed twice with DME, and plated to 
T-25 flasks coated with 0.1 mg/ml mouse collagen type IV and 0.1 mg/ml 
human fibronectin.
BMEC expression of CXCR7. Primary BMECs were treated with vari-
ous concentrations of IL-17, IL-1, TNF, and IFN- or left untreated for 24 h 
before undergoing total RNA isolation, as previously described (McCandless 
et al., 2006). QPCR analysis of CXCR7 was accomplished using a Taq-
man gene expression assay kit (Applied Biosystems), which uses the FAM/
TAMRA reporter with primers spanning the first and second exon and am-
plifies a 77-bp product. Calculated copies were normalized against copies of 
the housekeeping gene GAPDH.
Histological, IHC, and immunocytochemical analyses. Murine CNS 
tissues were isolated and frozen sections were permeabilized, blocked, and 
stained as previously described (McCandless et al., 2006). Histological anal-
yses, including myelin staining and IHC detection of CD31, CXCL12, 
VCAM-1, TNF, GFAP, CD3, and CD11b with nuclear ToPro3 counterstain-
ing, were performed as previously described (Gimenez et al., 2004; McCandless 
et al., 2008b).
Colocalization of CXCL12 and LAMP-1 within primary BMECs was 
performed after fixation with 4% paraformaldehyde for 10 min and permea-
bilization with block in 0.1% Triton X-100 and 10% goat serum for 30 min 
at room temperature. BMECs were incubated with the primary antibodies 
rabbit anti–human CXCL12 (PeproTech, 1:20) and rat anti–mouse LAMP-1 
(1:50; US Biologicals) in blocking buffer for 20 min at room temperature. 
Cells were washed three times in PBS, and then incubated in fluorescently 
conjugated goat anti–rabbit Alexa Fluor 555 and goat anti–rat Alexa Fluor 
488 (1:1,000; Invitrogen) secondary antibodies in blocking buffer for 15 min 
at room temperature. Cells were washed, counterstained with ToPro3, and 
coverslipped before being visualized on the confocal microscope and accom-
panying software.
Flow cytometry. Cells were isolated from the draining lymph nodes, 
spleens, and spinal cords of MOG-immunized CXCR7GFP/+ or C57BL/6 
mice at 9 d after immunization and stained with fluorescently conjugated 
antibodies to CD4, CD8, CD19, CD11b, CD11c, and CD45 as previously 
described (McCandless et al., 2006). Removal of spinal cords was accomplished 
genomic fragment including DNA sequence immediately downstream of 
stop codon of Cxcr7 gene was PCR amplified using C57BL/6 genomic 
DNA and cloned after a neomycin-resistant gene cassette flanked by Lox P 
sites. The sequence of the targeting construct was confirmed by DNA se-
quencing. The targeting construct was linearized by Not I restriction enzyme 
and electroporated into albino C57BL/6 embryonic stem (ES) cells. The col-
onies doubly resistant for the aminoglycoside G418 and ganciclovir were 
screened by Southern blot analyses with BsrgI, BamHI, and HindIII diges-
tions for homologous recombination. Positive clones were injected into 
mouse blastocysts. Mice were subsequently crossed with EIIa-cre to remove 
the neomycin-resistant cassette.
Analysis of CCX771 selectivity. Human neutrophils were isolated from 
whole blood and lymphocytes from buffy coats (Stanford Blood Center, 
Stanford, CA) via Ficoll-Paque PLUS centrifugation followed by red blood 
cell lysis. Lymphocyte fractions were activated in vitro, as previously de-
scribed (Walters et al., 2010). CEM, Molt-4, and U937 cells were obtained 
from American Type Culture Collection (ATCC) and cultured in RPMI-
1640 medium (Sigma-Aldrich) supplemented with 10% FBS. U937 cells 
were additionally treated with dibutyryl cyclic-AMP (Sigma-Aldrich). Baf3 
and L1.2 cells (ATCC) were stably transfected with human CCR5 and 
ChemR23, respectively, and were cultured in RPMI-1640 medium/10% 
FBS supplemented with murine IL-3. Chemokines were purchased from 
R&D Systems. Calcium flux, chemotaxis, and radioligand binding assays 
were all performed as previously described (Zabel et al., 2009; Walters et al., 
2010). Analysis of CCX771 activity against a panel of G protein–coupled re-
ceptors (GPCRs; Table S2) was conducted under contract by Cerep using the 
Non-Peptide Receptor Express Profile option (http://www.cerep.fr/cerep/
users/pages/downloads/pharmacology.asp).
Assessment of plasma concentrations of CCX771. A total of 12 male 
BALB/c mice (The Jackson Laboratory) were administered a subcutaneous 
injection of 10 mg/kg CCX771, formulated as a solution in 10% Captisol 
with dosing volume at 1 ml/kg. Plasma samples were obtained from retro-
orbital obtained blood (100 l) collected into EDTA tubes at determined time 
points. Each animal was bled only twice during the study; thus, each time-
point reflects data from three of the animals on study. After protein precipita-
tion, the supernatant solutions were analyzed by HPLC-MS/MS using a 
validated method (nominal plasma concentration; range from 1 to 1,000 ng/ml). 
Pharmacokinetic values for CCX771 were generated using noncompart-
mental analysis with WinNonlin Professional version 5.2 (Pharsight).
EAE induction and in vivo treatment with CCX771. Active EAE was 
induced in 8–12-wk-old female C57BL/6 (The Jackson Laboratory) mice 
by subcutaneous immunization with murine myelin oligodendroglial glyco-
protein peptide 35–55 (MOG; Sigma-Aldrich) and followed for clinical 
disease as previously described. MOG-specific T cells were generated as pre-
viously described (Gimenez et al., 2004). Activated cells were collected and 
transferred retroorbitally at 107 cells per mouse. Mice from all experiments 
were graded for clinical manifestations of EAE by the following criteria: 1, 
tail weakness; 2, difficulty righting; 3, hindlimb paralysis; 4, forelimb weakness 
or paralysis; 5, moribund or dead. CCX771 (ChemoCentryx) or vehicle 
(10% Captisol) was administered daily to mice subcutaneously at doses of 5, 
10, or 30 mg/kg in 100 ml of vehicle at the time of adoptive transfer of T cells 
or when mice achieved a clinical score of 1.
LFB staining of spinal cord. Frozen sections were stained for myelin using 
0.1% LFB and counter stained with 0.1% cresyl violet. The sections were dif-
ferentiated with 0.5% lithium carbonate, counterstained with cresyl violet for 
20 min, and mounted for imaging using an Axioskop 40 light microscope 
(Carl Zeiss, Inc.).
Assays of T cell proliferation and cytokine expression. MOG-specific 
T cell lines underwent three 7-d rounds of restimulation in the presence of 
irradiated splenocytes (ratio 1:5), 0.01 mg/ml MOGp35-55, and IL-2, IL-12, 
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via pressure-syringing using an 18 gauge needle. Data collection and analysis 
were conducted using a FACSCalibur flow cytometer using CellQuest soft-
ware (BD), as previously described (McCandless et al., 2009).
Generation of mCherryCXCL12 and internalization experiments. 
mCherry plasmid DNA was used to transfect 293T cells as previously de-
scribed (Luker et al., 2009). Supernatants containing mCherry-CXCL12 
were collected 24 h after transfection. To assess mCherry CXCL12 uptake, 
BMECs were treated with IL-17 (100 ng/ml), IL-1 (10 ng/ml), IFN- (100 
ng/ml) or control media for 24 h in media containing vehicle, CXCR7 an-
tagonist, CCX771, or anti-CXCR4 antibody (R&D Systems). BMECs were 
incubated for 2 h with mCherry-CXCL12 supernatants, and then fixed with 
ice-cold methanol for 10 min. Cells were then counterstained with ToPro3 
and visualized immediately, or further stained with LAMP-1 as described in 
Histological, IHC, and immunocytochemical analyses.
Statistical analyses. All values are expressed as mean ± SEM. Student’s t test 
was used to determine the statistical significance of QPCR and histological 
and flow cytometry analyses. Mean maximal disease severity significance was 
determined by the Mann-Whitney nonparametric test, with values of P < 
0.05 considered statistically significant for all analyses. Statistical significance 
of disease severity curves, effects of cytokines on CXCR7 expression, and 
activity in BMECs and in vivo CXCL12 internalization was determined 
using one-way Analysis of Variance (ANOVA) with Bonferroni’s multiple com-
parison test.
Online supplemental material. Fig. S1 depicts the generation of CXCR7 
GFP knock-in mice. Fig. S2 shows that CXCR7 antagonism prevents demy-
elination during EAE. Fig. S3 shows that CXCR7 antagonism does not affect 
MOG-specific T cell reactivation. Fig. S4 shows cytokine levels within spinal 
cord parenchyma in mice treated with vehicle versus CXCR7 antagonist and 
that BMEC internalization of CXCL12 does not require CXCR4. Fig. S5 
depicts abluminal CXCL12 at post-capillary venules during EAE induced 
by adoptive transfer of MOG-specific CD4+ T cells and immunization with 
MOG. Fig. S6 shows that CXCR7 antagonism does not alter CXCL12 
mRNA levels in BMECs or in spinal cords of mice with EAE.
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